Published Case Study Demonstrates the Clinical Utility of Biocept's Liquid Biopsy Test for ALK Rearrangements
"Identifying clinically actionable biomarkers is critical for selecting appropriate therapy aimed at improving outcomes for patients with cancer," said Alejandro R. Calvo, MD, FACP, Associate Professor of Medicine,
"We believe that demonstrating clinical utility in clinical settings is important for enhancing further adoption of our Target Selector™ assays," said
About Oncology & Hematology Review
Oncology & Hematology Review is a peer-reviewed, open-access, bi-annual journal comprised of review articles, case reports, practice guides and theoretical discussions. Published each Spring and Fall, the journal aims to help time-pressured physicians to stay abreast of key advances and opinions in oncology practice.
ALK gene rearrangements are found in 2-7% of non-small cell lung cancer (NSCLC) cases, and detection is used to qualify patients for possible therapeutic intervention. Detection of an ALK fusion is used to determine the likelihood of response to crizotinib (Xalkori®) or ceritinib (Zykadia®), two commercially available tyrosine kinase inhibitors. Additionally, alectinib (Alecensa®) and brigatinib (Alunbrig®) are approved for patients with ALK-positive metastatic NSCLC who have progressed on or are intolerant to crizotinib.
For more information on
Forward-Looking Statements Disclaimer Statement
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. To the extent that statements in this release are not strictly historical, including without limitation statements as to our ability to improve the outcomes of patients diagnosed with cancer, the further adoption of our Target Selector assays, and whether additional clinical case studies will be published this year supporting the use of our liquid biopsy platform , such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our
View original content with multimedia:http://www.prnewswire.com/news-releases/published-case-study-demonstrates-the-clinical-utility-of-biocepts-liquid-biopsy-test-for-alk-rearrangements-300637816.html
Investor, LHA Investor Relations, Jody Cain, Jcain@lhai.com, 310-691-7100, or Media, Trevelino/Keller, Colleen Murphy, firstname.lastname@example.org, 404-214-0722, Ext. 109